Share this article and save a life!
Everyone thinks this is a healthcare ban. It is not. 📋
CMS just finalized a rule that removes federal Medicaid and CHIP dollars from gender-transition procedures for minors. But the rule itself explicitly states that it does not prohibit providers from furnishing these procedures, and it does not prevent states from covering them.
That distinction matters enormously for how health systems and state agencies need to respond.
Here is what the rule actually does, straight from the Federal Register:
• Medicaid: federal matching funds are prohibited for these procedures for anyone under 18
• CHIP: the same prohibition applies through age 18, meaning individuals under 19
• Effective date: October 12, 2026, which is 60 days after publication
• Transition window: states may continue claiming federal financial participation for cross-sex hormone therapy for beneficiaries already receiving it, for up to six months from the effective date
• States wishing to continue coverage may do so entirely with state-only funds
The rule is 212 pages long. It amends 42 CFR parts 441 and 457.
According to TIJ News, the preamble cites an HHS evidence review first released in May 2025 and finalized after peer review in November 2025 as the scientific grounding for the policy. It also counts 27 states and one territory that have already enacted laws restricting these procedures for minors at the state level.
What most people are missing is the financial architecture shift, not the clinical one.
This is a federal matching funds decision. The federal government is not telling doctors what to do. It is telling states what it will and will not pay for. That is a fundamentally different lever, and one that is extremely hard to challenge in court compared to an outright clinical prohibition.
The real-world implication is this: states that want to maintain coverage will now absorb the full cost with no federal match. That is a significant budget pressure, particularly for states with large Medicaid populations and already strained budgets.
Provider organizations and state Medicaid agencies have roughly two months to figure out their coverage posture, their billing workflows, and how to handle the six-month transition window for patients currently on hormone therapy.
Save this post if you need to brief leadership on the timeline. The October 12, 2026 effective date is coming fast.
The question this leaves me sitting with: when the federal government stops paying for something, it does not make the need disappear. It just shifts who absorbs the cost and the consequence. That is worth thinking hard about, regardless of where you stand on the underlying policy.
👉 Follow Jonathan Govette, CEO of Oatmeal Health, for daily healthcare insights on LinkedIn. Deeper dives in The Oatmeal Bite on Substack: https://news.oatmealhealth.com
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
